Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

959
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
959
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

801
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
801

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinical evidence for immune cell-based therapy for head and neck cancer: A systematic review and meta-analysis.

Critical reviews in oncology/hematology·2026
Same author

Advances in Biomass-Derived and Biodegradable Polymer Materials: Synthesis and Application.

Materials (Basel, Switzerland)·2026
Same author

Development and computational analysis of high dimensional spectral flow cytometry data for the resolution of innate lymphoid cells in the mammary tumor microenvironment.

Frontiers in immunology·2026
Same author

Systematic Control of Epoxidation in Low-cis Hydroxyl-Terminated Polybutadiene (HTPB) and Its Impact on Polyurethane Properties.

Polymers·2026
Same author

Biodegradable Plastics as Sustainable Alternatives: Advances, Basics, Challenges, and Directions for the Future.

Materials (Basel, Switzerland)·2025
Same author

Adoptive Cellular Therapies in Pediatric Leukemia Patients After Allogeneic-Hematopoietic Stem Cell Transplants.

Immune network·2025

相关实验视频

Updated: Jul 17, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

625

使用全源双阴性CD4-CAR-T细胞向T细胞恶性瘤.

Karen Kai-Lin Fang1,2, Jongbok Lee1, Ismat Khatri1

  • 1Toronto General Hospital Research Institute, Toronto, Ontario, Canada.

Journal for immunotherapy of cancer
|September 7, 2023
PubMed
概括

用抗CD4仿真抗原受体 (CAR4) - DNTs进行基因工程的全原双阴性T细胞 (DNTs) 对T细胞恶性瘤具有强大的抗瘤活性. 这种CAR4-DNT疗法为患有复发/耐药T细胞急性淋巴细胞白血病和外围T细胞淋巴瘤的患者提供了一个有前途的新治疗方案.

关键词:
这是T-淋巴细胞.血液学上的新生病.免疫疗法 免疫疗法受体,仿真抗原受体,仿真抗原受体

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

942
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K

相关实验视频

Last Updated: Jul 17, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

625
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

942
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法
  • 在瘤学瘤学.

背景情况:

  • 复发性/耐药性T细胞恶性瘤的治疗选择有限.
  • 化学抗原受体 (CAR) -T细胞疗法在T细胞恶性瘤中面临挑战,原因是潜在的污染和兄弟杀戮.
  • 全基双阴性T细胞 (DNTs) 是一个安全的,现成的细胞疗法候选人,可接受CAR转导.

研究的目的:

  • 探索异性DNTs对T细胞恶性瘤的抗瘤活性.
  • 评估抗CD4-CAR (CAR4) -DNTs在T细胞恶性瘤中采用细胞疗法的潜力.

主要方法:

  • 健康的捐赠者衍生的异性DNTs的ex vivo扩张和CAR4转导.
  • 使用细胞毒性测定和异种移植模型,评估DNT和CAR4-DNT对T细胞急性淋巴细胞白血病 (T-ALL) 和外围T细胞淋巴瘤 (PTCL) 的抗瘤活性.
  • 通过过井和阻断测试来研究作用机制.

主要成果:

  • 基DNTs在体外证明了对T-ALL和PTCL的内源性细胞毒性,在体内需要高剂量.
  • CAR4转导显著增强了DNT功效,CAR4-DNTs对CD4+T-ALL和PTCL具有优越的细胞毒性.
  • 在异种移植模型中,CAR4-DNTs有效地消除了T-ALL和PTCL细胞系和初级爆发,透瘤,延迟进展和延长存活. 用idelalisib进行预治疗提高了CAR4-DNT的持久性和有效性.
  • 这些机制涉及LFA-1,NKG2D,以及穿孔素/granzyme B通路.

结论:

  • 全基性CAR4-DNTs表明有效向T细胞恶性瘤.
  • CAR4-DNTs代表了T细胞恶性瘤 (如T-ALL和PTCL) 的可行的采用细胞疗法.